Effects of Dapagliflozin and Empagliflozin in Myocardial Dysfunctio

Phase 3

Recruiting

Conditions: Condition 1: Heart failure. Condition 2: Myocardial infarction.
Heart failure
ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction

Registration Number: IRCT20111206008307N45

Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 75

Inclusion Criteria

Heart Failure with Reduced Ejection Fraction
Aged 18 to 80 years
Consented patients

Exclusion Criteria

Pregnancy
Lactation
Liver failure
Renal failure (estimated glomerular filtration rate less than 30 ml/min)
Patients with a history of taking dapagliflozin or empagliflozin
Diabetes mellitus
Contraindications of dapagliflozin or empagliflozin
Inflammatory and autoimmune diseases
Systolic blood pressure less than 100 or more than 180 mm Hg
Symptomatic hypotension
Malignancy

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ew York Heart Association (NYHA) Functional Classification. Timepoint: At baseline and 40 days after intervention. Method of measurement: Assessment by one cardiologist.

Secondary Outcome Measures

Name	Time	Method
High-sensitivity C-reactive protein (hs-CRP). Timepoint: At baseline and 40 days after intervention. Method of measurement: Laboratory test.;NT-proBNP. Timepoint: At baseline and 40 days after intervention. Method of measurement: Laboratory test.;Ejection fraction. Timepoint: At baseline and 40 days after intervention. Method of measurement: Echocardiography.;Left ventricular end-diastolic volume. Timepoint: At baseline and 40 days after intervention. Method of measurement: Echocardiography.;Hospitalization due to cardiovascular reasons. Timepoint: Within 40 days after intervention. Method of measurement: Interview.